Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Immunotherapy is a novel way to treat cancer and does so by targeting the immune system to
destroy tumor cells. Many different therapeutic vaccines have been evaluated in phase 1, 2,
and even phase 3 trials. Much has been learned about the principles of applying immune-based
therapies and specifically the types of patients that may be most likely to mount an
effective immune response. When used alone, cancer vaccines may have their greatest impact
earlier in the disease course or in situations with minimal residual disease.
ImmunoVaccine Technologies Inc. (Immunovaccine) is an immuno-oncology company developing a
novel adjuvanting technology platform termed DepoVax. DepoVax was created to enhance the
speed, strength and duration of an immune response. The peptide antigens included in
DPX-Survivac are designed to target Survivin, a protein which is over-expressed in many
cancer types, including epithelial ovarian cancers.
This study was designed be a phase 1-2 trial to determine the safety and immunogenicity
profiles of DPX-Survivac, a therapeutic vaccine co-administered with a regimen of low dose
oral cyclophosphamide. The dosing-finding phase 1 study of 15 subjects would move directly
into a randomized phase 2 study. However, with the evolving field of immunotherapy
Immunovaccine has begun to focus on combination therapies, combining DPX-Survivac treatment
with checkpoint inhibitors and other immune modulators, such as in NCT02785250.
Phase:
Phase 1
Details
Lead Sponsor:
ImmunoVaccine Technologies, Inc. ImmunoVaccine Technologies, Inc. (IMV Inc.)